Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06AVM
|
|||
| Former ID |
DIB018962
|
|||
| Drug Name |
beta3-tetrapeptide
|
|||
| Synonyms |
beta3-tetrapeptide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C35H46N6O7
|
|||
| Canonical SMILES |
CC1C(CC(=O)O1)NC(=O)CC(CCCCN)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)CC(CC4=CC(=CC=C4)O)NC(=O)C
|
|||
| InChI |
1S/C35H46N6O7/c1-21-30(19-34(46)48-21)40-32(44)17-25(9-5-6-13-36)39-35(47)31(16-24-20-37-29-12-4-3-11-28(24)29)41-33(45)18-26(38-22(2)42)14-23-8-7-10-27(43)15-23/h3-4,7-8,10-12,15,20-21,25-26,30-31,37,43H,5-6,9,13-14,16-19,36H2,1-2H3,(H,38,42)(H,39,47)(H,40,44)(H,41,45)/t21-,25+,26+,30-,31?/m1/s1
|
|||
| InChIKey |
GQYXVIIYXPRQJK-JZYDGZRSSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Somatostatin receptor type 4 (SSTR4) | Target Info | Agonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Pathwhiz Pathway | Gastric Acid Production | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2078). | |||
| REF 2 | Beta(2)/beta(3)-di- and alpha/beta(3)-tetrapeptide derivatives as potent agonists at somatostatin sst(4) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Feb;367(2):95-103. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.